Avapritinib
Avapritinib 300 mg
300 mg · ITT
3L or later GIST (n = 240)
Comparator: regorafenib 160 mg
median progression-free survival: 4.2 months, primary analysis
VOYAGER · NCT03465722
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
GIST pipeline
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
18 arms have a reported figure in this set.
Avapritinib 300 mg
300 mg · ITT
3L or later GIST (n = 240)
Comparator: regorafenib 160 mg
median progression-free survival: 4.2 months, primary analysis
VOYAGER · NCT03465722
Regorafenib 160 mg
160 mg · ITT
3L or later GIST (n = 236)
median progression-free survival: 5.6 months, primary analysis
VOYAGER · NCT03465722
Bezuclastinib 600 mg + sunitinib 37.5 mg
600 mg + 37.5 mg · ITT
GIST after imatinib (n = 204)
Comparator: sunitinib 37.5 mg
median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025
Peak · NCT05208047
Sunitinib 37.5 mg continuous
37.5 mg · ITT
GIST after imatinib (n = 209)
median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025
Peak · NCT05208047
Imatinib 400 mg daily
400 mg · ITT
unresectable or metastatic KIT (CD117) positive GIST
median progression-free survival: 18.9 months, median follow up 37.5 months
Imatinib 800 mg daily
800 mg · ITT
unresectable or metastatic KIT (CD117) positive GIST
Comparator: imatinib 400 mg
median progression-free survival: 23.2 months, median follow up 37.5 months
NB003, 2L to 4L or later
not stated in source · Single arm
GIST 2L to 4L or later (n = 158)
median progression-free survival: 9.2 months, data as of March 2025
NB003 Phase 1 · NCT04936178
NB003, 3L subgroup
not stated in source · Single arm
GIST 3L (n not stated in source)
median progression-free survival: 13.7 months, data as of March 2025
NB003 Phase 1 · NCT04936178
Olverembatinib 30 to 50 mg every other day
30 to 50 mg · Single arm
SDH-deficient GIST (n = 26)
median progression-free survival: 25.7 months, cutoff 11.13.2025
HQP1351SJ0003 · NCT03594422
Regorafenib 160 mg, 3 weeks on 1 off
160 mg · ITT
GIST after imatinib and sunitinib
Comparator: placebo
median progression-free survival: 4.8 months, primary analysis
GRID · NCT01271712
Placebo
placebo · ITT
GIST after imatinib and sunitinib
median progression-free survival: 0.9 months, primary analysis
GRID · NCT01271712
Ripretinib 150 mg
150 mg · ITT
GIST after imatinib, sunitinib and regorafenib
Comparator: placebo
median progression-free survival (BICR): 6.3 months, primary analysis
INVICTUS · NCT03353753
Placebo
placebo · ITT
GIST after imatinib, sunitinib and regorafenib
median progression-free survival (BICR): 1 months, primary analysis
INVICTUS · NCT03353753
Ripretinib 150 mg
150 mg · ITT
GIST after imatinib (ITT n = 226)
Comparator: sunitinib 50 mg 4/2
median progression-free survival (IRR), ITT: 8 months, primary analysis
median progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysis
median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P
INTRIGUE · NCT03673501
Sunitinib 50 mg 4/2
50 mg · ITT
GIST after imatinib (ITT n = 227)
median progression-free survival (IRR), ITT: 8.3 months, primary analysis
median progression-free survival, KIT exon 11 ITT: 7 months, primary analysis
median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratory
median PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory
INTRIGUE · NCT03673501
Sunitinib 50 mg, 4 weeks on 2 off
50 mg · ITT
GIST after imatinib progression or intolerance
Comparator: placebo
median time to tumor progression: 27.3 weeks, interim analysis
median progression-free survival: 24.1 weeks, interim analysis
Study 1 · NCT00075218
Placebo
placebo · ITT
GIST after imatinib progression or intolerance
median time to tumor progression: 6.4 weeks, interim analysis
median progression-free survival: 6 weeks, interim analysis
Study 1 · NCT00075218
Velzatinib 300 mg tablet (or 400 mg capsule), 2L
300 mg · Single arm
2L advanced GIST (n = 46)
median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025
StrateGIST 1 · NCT05489237
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.